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LETTERS TO THE EDITOR
Caudal Border of Level
2R in the New
International Lymph
Node Map for Lung
Cancer
To the Editor:
Recently, the International Asso-
ciation for the Study of Lung Cancer
(IASLC) proposed a new lymph node
map1 that was published in “Staging
Manual in Thoracic Oncology.”2 This
lymph node map was created by the
integration of information obtained
worldwide, and the members of the
IASLC staging committee have worked
diligently toward establishing it. It is
essential for significant analysis and re-
vision toward the next eighth edition of
tumor, node, metastasis (TNM) classifi-
cation that we have a good understand-
ing of this map and endeavor to operate
the seventh edition of TNM classifica-
tion properly. However, for the proper
operation of this map, we need to cor-
rectly identify the lower border of level
2R. This border is defined as “the inter-
section of the caudal margin of the in-
nominate vein with the trachea.” Unfor-
tunately, by referring the manual,2 we
could not identify the lower border of
level 2R. Initially, we literally inter-
preted this definition and drew line “a,”
(Figure 1A), which was obtained by
marking the line of overlap of the caudal
margin of the innominate vein and the
trachea. After studying the figures in the
article1 and the manual,2 we think that
the border should be horizontal for the
convenience of computed tomography-
based diagnosis and staging. From the
definition of line “a,” it seems that this
line will mostly be diagonal; this will
make computed tomography-based di-
agnosis difficult as mentioned before.
Therefore, we think that two more bor-
ders could be drawn in Figure 1A as
follows: (1) line “b” can be drawn hor-
izontally from the intersection of the
caudal margin of the innominate vein to
the right margin of the trachea and (2)
line “c” can be drawn horizontally from
the caudal point of confluence of the
innominate vein and the superior vena
cava (SVC). However, there would be
drawbacks to using both these lines too,
even though they are horizontal. In the
case of line “b,” the required intersec-
tion point through which this line passes
would be absent in cases where the left
margin of the SVC overlaps with the
trachea. For line “c,” there would be
some difficulties in identifying the point
of confluence of the innominate vein
with the SVC. These difficulties can be
overcome if it is clarified whether the
lymph node illustrated in Figure 1B is
level 2R or level 4R. We hope the
IASLC will help us bridge the informa-
tion gap between the sixth and seventh
editions of the TNM classification for
lung cancer.
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Response to Letter to
the Editor
In Response:
We thank Ichimura et al.1 for their
careful review of our article proposing a
new international lymph node map for
the staging of lung cancer (International
Association for the Study of Lung Can-
cer [IASLC] lymph node map). They
raise a question about the border be-
tween the upper and lower right paratra-
cheal lymph nodes at levels 2R and 4R.
We proposed that this border be defined
as the intersection of the caudal margin
of the innominate vein with the trachea.
Ichimura et al. correctly pointed out that
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FIGURE 1. A, Superior vena cava (SVC). The schema shows the mediastinum in
the region of the trachea, the right and left main bronchi, the innominate vein,
and the SVC. The dotted line “a” and the solid lines “b” and “c” demarcate the
possible borders of level 2R. B, SVC. The arrow indicates a lymph node.
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the orientation of the innominate vein to
some degree is diagonal and proposed
that a horizontal line drawn at either of
the two points of the intersection of the
vein with the trachea be used as the
border between levels 2R and 4R lymph
nodes. However, in developing the
IASLC lymph node map, we explicitly
intended to minimize the use of arbitrary
nonanatomic and, thus, not easily repro-
ducible boundaries between lymph node
levels. Although somewhat diagonal in
orientation, the inferior border of the
innominate vein is easily visible by
computed tomography, especially when
intravenous contrast is used, and is an
internationally reproducible landmark.
Therefore, we feel that this is more ac-
curate way to distinguish between levels
2R and 4R. As illustrated in Figure “B”
of their article, some lymph nodes will
overlap the borders between lymph node
levels no matter how these are defined
and will need to be labeled according to
where they predominantly reside. The
lymph node shown in Figure “B” is
predominantly located below the caudal
margin of the innominate vein and
would, therefore, probably be most ap-
propriately labeled as a 4R node.
The title of our article indicated
that the IASLC map was a proposal for
a new international lymph node map.
We are grateful for the careful study of
this proposal by other authors, because it
is precisely through thoughtful com-
mentary that this map may be improved
in the future. Our principal intent was to
develop international nomenclature that
can now be used in the prospective
IASLC (and other) lung cancer data-
bases. This will permit future analyses
that may refine the N-stage descriptors
in the next (eighth) edition of the staging
manuals.
Valerie W. Rusch, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
Hisao Asamura, MD
National Cancer Center Hospital
Tokyo, Japan
Peter Goldstraw, MD
Royal Brompton Hospital
London, UK
ruschv@mskcc.org
REFERENCE
1. Rusch VW, Asamura H, Watanabe H, et al;
Members of IASLC Staging Committee. The
IASLC lung cancer staging project: a proposal
for a new international lymph node map in the
forthcoming seventh edition of the TNM clas-
sification for lung cancer. J Thorac Oncol
2009;4:568–577.
Cavitary Lung Cancer
with an Aspergilloma-
Like Shadow
To the Editor:
Pulmonary aspergilloma is a clump
of fungus that forms in a pulmonary cavity
and presents a characteristic chest radio-
graphic appearance called a fungus ball.1
In contrast, lung cancer often forms a
cavity with an irregular, thickened wall,
but rarely shows a fungus ball-like shad-
ow.2 We describe the rare case of a can-
cerous mass arising from the cavity wall
showing a fungus ball-like shadow.
An 84-year-old man was noted to
have a cavitary lesion in the left lower
lung field on chest x-ray at a medical
checkup. Chest computed tomography
(CT) performed in another hospital re-
vealed a fungus ball-like mass in the
cavity, and he was diagnosed with as-
pergillosis, which was treated with oral
medication. Because the intracavitary
lesion showed a tendency to enlarge on
CT, he visited our outpatient clinic for a
second opinion.
Chest CT showed a 5-cm cavity
with an area of irregular thickening in the
basal segment of the left lung (Figure 1A).
The cavity contained a mass growing in a
polypoid manner from the ventral side and
occupying about half of the cavity vol-
ume. The ineffectiveness of antifungal
agents, tendency of the mass to enlarge
overtime, irregular thickening of the cav-
ity wall, and absence of mobility of the
fungus ball with a change in the patient’s
position led to a strong suspicion of lung
cancer rather than aspergillosis. We per-
formed bronchoscopy and diagnosed him
with adenocarcinoma on brush cytology
of the intracystic mass. The patient under-
went left lower lobectomy with hilar and
mediastinal lymph node dissection. On
gross examination, the resected specimen
showed a grayish-white, solid, polypoid
mass with an irregular surface in the cyst
(Figure 1B). Histologically, papillary ade-
nocarcinoma proliferated invasively at the
intracystic mass and the cyst wall. There
was n2 metastasis at the carinal lymph
nodes (p-T2N2M0, stage IIIA). No fungal
elements were detected microscopically.
It is known that cancerous cavi-
ties often have a thick wall with an
irregular inner surface.3 Part of the
wall may project into the cavity, form-
ing a so-called mural nodule. In this
case, the mural nodule possibly grew
to be a polypoid mass in the cavitary
lung cancer.
It is relatively straightforward to
diagnose pulmonary aspergillosis be-
cause of its characteristic fungus ball-
like appearance. In addition, the mobil-
ity of a fungus ball with a change in the
patient’s position is helpful for the diag-
nosis. In this case, chest CT in the su-
pine position revealed that an intracavi-
tary tumor had grown from the ventral to
luminal side, which failed to move with
a change in position, suggesting that an
aspergilloma was unlikely.
When a chest x-ray shows a char-
acteristic, fungus ball-like shadow, it
tends to suggest a pulmonary aspergil-
loma. Indeed, the patient was initially
diagnosed with aspergillosis and treated
with oral medication. As a result, it took
a long time to diagnose lung cancer cor-
rectly. Thus,we should always consider
malignant diseases, such as lung cancer
and concomitant aspergillosis, and per-
form a test for fungus-ball mobility with a
change in position, bronchoscopy, and
histopathologic examination.
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